Building Lipedema Research Resources

Last updated: March 11, 2025
Sponsor: Vanderbilt University Medical Center
Overall Status: Active - Enrolling

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT06180850
212427
  • Ages 18-80
  • Female
  • Accepts Healthy Volunteers

Study Summary

Lipedema is a disease marked by subcutaneous adipose tissue accumulation in the lower extremities of females that is accompanied by somatic pain and edema. Importantly, lipedema is commonly misdiagnosed as obesity, although it's estimated to affect a high 11% of women. Clinical diagnosis of lipedema requires specialized training not widely available at most major medical centers, and there remains a substantial need for objective tools to distinguish lipedema from obesity. There is a critical need to define specific molecular markers of disease in circulation or at the tissue-level. The purpose of this study is to create, manage, and characterize an innovative lipedema biorepository. The goal of the biorepository will be to better understand disease mechanisms of lipedema and to define specific molecular markers of disease in circulation or at the tissue-level. The long-term purpose of our studies are to help with prevention and early management of lipedema.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants with or without lipedema

  • Age range = 18-80 years

  • Participants with lipedema have a formal diagnosis by a physician using criteria inAppendix A of protocol

  • Female

Exclusion

Exclusion Criteria: Volunteers in the lipedema or control group will be excluded with the following:

  • Pregnant or breast-feeding

  • Taking any anticoagulation or antiplatelet therapy other than aspirin (up to 100 mgdaily)

  • Active infection anywhere in the body, or open wound on the lower-extremities or atlocations for ultrasound, bioimpedance, and tissue dielectric measurements

  • Battery-operated device implanted that cannot be removed for ultrasound, DXA scan,bioimpedance, and tissue dielectric measurements

  • Primary lymphedema

  • Uncontrolled diabetes, renal disease, thyroid disease, or hypertension

  • Hormone dysregulation or another significant clinical condition affecting hormonestatus as confirmed by clinical co-investigators

  • Bone metastases

  • Contrast imaging scan in the previous 7 days

  • Nuclear medicine scan in previous 3 days

  • Lumbar spine fusion

  • Weigh more than 500 lb (226.8 kg)

Also excluded are subjects incapable of giving informed written consent:

  • Subjects who have an inability to communicate with the researcher for any reason

  • Subjects who are non-English speaking who cannot communicate through a translator,or if a translator is not available

  • Subjects who cannot adhere to the experimental protocols for any reason

  • Subjects who have limited mental ability to give informed consent due to mentaldisability, confusion, or psychiatric disorders

  • Prisoners

Study Design

Total Participants: 200
Study Start date:
February 23, 2024
Estimated Completion Date:
October 01, 2026

Connect with a study center

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37203
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.